Quality Systems

FDA has released Guidance for Industry: Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination.

FDA inspections of compounding pharmacies manufacturing sterile-drug products lead to voluntary recalls.

An introduction to the upcoming Interphex panel--Lessons Leaned: Successes and Challenges in Implementing Quality by Design.? Moderator: Jennifer Markarian, manufacturing editor, Pharmaceutical Technology. Panelists: John Lepore, senior director of Chemical Process Development and Commercialization for Global Pharmaceutical Commercialization at Merck and Co. Chris Moreton, FinnBrit Consulting Jonathon Thompson, senior manager of Compliance Services Consulting at Invensys Operations Management

FDA's Fiscal Year 2014 budget request includes more than $10 million above the 2012 budget for inspections of products manufactured in China.

FDA inspections of compounding pharmacies manufacturing sterile products reveal non-sterile conditions.

Prefilled-syringe line features automation and novel disinfection techniques.

Company is notified of GMP violations at facility in Catania, Italy.

FDA Releases Guidance on Self-Selections Studies

USP has inaugurated the first satellite site of the USP Spectral Library Global Laboratory Network in China.

Ruling has implications for intellectual property protection for innovator drugs in India.

Latin America's diverse growing market seeks regulatory harmonization.

Industry is moving toward closed-loop control of continuous processing.

The authors describe a method-validation-by-design (MVbD) approach to validate a method over a range of formulations using both design-of-experiment and quality-by-design principles to define a design space that allows for formulation changes without revalidation.

The mysteries of rounding are exposed; strict, unbiased rounding can be applied.

Novartis loses an appeal in seeking patent protection in India for its anticancer drug.

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.

Strengthening government control or striving for compliance with international standards?

David Elder, vice-president, technical at PAREXEL, discusses US legislation allows for inspection of generic-drug activities.

Draft guidance combines and supersedes previous guidance documents.

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

In the context of international trade, the need to develop global quality standards for medicines is increasing.

FDA's Brian Hasselbalch provides an overview of trends found in FDA quality inspections over the past year.

Latest news about compound pharmacies, biosimilars, prescription drug purchases, and other regulatory topics.

The European Union authorities are stepping up their efforts to incorporate quality-by-design principles into their regulations and guidelines.

Keith Bader, senior director of technology at Hyde Engineering + Consulting discusses his presentation ?Establishing a design space: cleaning process development and validation,? which will be presented at Interphex 2013